BioCentury | Aug 14, 2020
Deals

Industry executives see M&A opportunities during COVID-19

M&A drives growth, and smaller companies are likely continue to be picked off rather than grow into big biotechs, according to a panel of industry executives. BioCentury hosted a webinar on Aug. 12...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...PLAU, in Phase II testing for pancreatic cancer and preclinical testing for solid tumors. TARGET/MARKER/PATHWAY: Urokinase-type plasminogen activator...
...Phase II testing for pancreatic cancer and preclinical testing for solid tumors. TARGET/MARKER/PATHWAY: Urokinase-type plasminogen activator (PLAU; uPA...
...email: mkelso@uow.edu.au CONTACT: Marie Ranson, same affiliation as above email: mranson@uow.edu.au Chris Lieu University of Wollongong Urokinase-type plasminogen activator (PLAU) (uPA) Pancreatic...
BioCentury | Nov 12, 2015
Product R&D

Probodies, anticancer

...cells was more than 1,000-fold lower than Ab-TCBs alone or Pb-TCBs in the presence of PLAU...
...CD274 ) - Programmed cell death 1 ligand 1 PLAU ( uPA ) - Urokinase-type plasminogen activator...
BioCentury | May 7, 2015
Translation in Brief

NYU cuts to the bone with MRCT

New York University School of Medicine expects its recent deal with the not-for-profit MRC Technology will help the university extract more value from its therapeutic targets than if it had partnered them with a biotech...
BioCentury | Jul 14, 2014
Company News

Wilex, RedHill deal

...and metastatic breast cancer. The product is a second-generation serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA...
BioCentury | May 12, 2014
Clinical News

A6: Phase II started

...A6 Business: Cancer Molecular target: NA Description: Anti-angiogenic peptide derived from urokinase plasminogen activator ( uPA...
BioCentury | Apr 7, 2014
Company News

Link Health, Wilex deal

...and metastatic breast cancer. The product is a second-generation serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA...
BioCentury | Feb 3, 2014
Company News

Wilex cancer news

...an RCC diagnostic imaging agent. Mesupron is a second-generation serine protease inhibitor targeting urokinase-type plasminogen activator ( uPA...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

...Hsp90) inhibitor Ph II Wilex AG (Xetra:WL6) Mesupron (WX-671) Second-generation serine protease inhibitor of urokinase-type plasminogen activator (uPA...
BioCentury | Nov 15, 2012
Distillery Techniques

Technology: Drug platforms

...an albumin-binding peptide could increase therapeutic duration. In mice, a bicyclic peptide targeting urokinase-type plasminogen activator (PLAU; uPA...
Items per page:
1 - 10 of 72